Meticillin-resistant Staphylococcus aureus

Autor: Barry Cookson, Christina M. J. E. Vandenbroucke-Grauls, Satoshi Hori, Jaana Vuopio-Varkila, Sesin Kocagöz, A. Yasemin Öztop, John M. Boyce, Didier Pittet, Keryn Christiansen, Stéphan Juergen Harbarth
Přispěvatelé: AII - Amsterdam institute for Infection and Immunity, Medical Microbiology and Infection Prevention, VU University medical center
Jazyk: angličtina
Rok vydání: 2005
Předmět:
Zdroj: Lancet infectious diseases, 5(10), 653-663. Lancet Publishing Group
The Lancet. Infectious Diseases
Lancet Infectious Diseases, 5(10), 653-663. Lancet Publishing Group
Boyce, J M, Cookson, B, Christiansen, K, Hori, S, Vuopio-Varkila, J, Kocagoz, S, Oztop, A Y, Vandenbroucke-Grauls, C M J E, Harbarth, S & Pittet, D 2005, ' Meticillin-resistant Staphylococcus aureus ', Lancet Infectious Diseases, vol. 5, no. 10, pp. 653-663 . https://doi.org/10.1016/S1473-3099(05)70243-7
The Lancet Infectious Diseases, Vol. 5, No 10 (2005) pp. 653-663
ISSN: 1473-3099
DOI: 10.1016/S1473-3099(05)70243-7
Popis: Meticillin was introduced in 1959 to treat infections caused by penicillin-resistant Staphylococcus aureus. In 1961 there were reports from the UK of S aureus isolates that had acquired resistance to meticillin (meticillin-resistant S aureus, MRSA). Similar MRSA isolates were soon found in other European countries, and later from Japan, Australia, and the USA. Today MRSA is a major cause of hospital-acquired infections, and a serious public-health concern. In this forum, we present different perspectives from across the globe to better understand the complexity of the problem, and examine the challenges that individual countries face in trying to control the spread of MRSA
Databáze: OpenAIRE